Back to results

CompletedPhase 2

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Pfizer Investigational Site

Dallas, Texas, United States

+19 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2002-01
Enrollment: 111 participants
Sponsor: Pfizer
Purpose: treatment

Locations (20)

Pfizer Investigational SiteDallas, Texas, United States
Pfizer Investigational SiteAntwerp, Belgium
Pfizer Investigational SiteBrussels, Belgium
Pfizer Investigational SiteLeuven, Belgium
Pfizer Investigational SiteNamur, Belgium
Pfizer Investigational SiteWilrijk, Belgium
Pfizer Investigational SitePorto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational SiteSão Paulo, São Paulo, Brazil
Pfizer Investigational SiteSydney, Nova Scotia, Canada
Pfizer Investigational SiteBogotá, Bogota . DC, Colombia
Pfizer Investigational SiteCali, Colombia
Pfizer Investigational SiteHyderabad, Andhra Pradesh, India
Pfizer Investigational SiteBangalore, Karnataka, India
Pfizer Investigational SiteMumbai, Maharashtra, India
Pfizer Investigational SitePune, Maharashtra, India
Pfizer Investigational SiteGuadalajara, Jalisco, Mexico
Pfizer Investigational SiteMexico City, Mexico City, Mexico
Pfizer Investigational SiteLima, Lima Province, Peru
Pfizer Investigational SiteLima, Lima Province, Peru
Pfizer Investigational SiteManila, Philippines

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen — TrialFind